1. Phase 2 study of all‐oral ixazomib, cyclophosphamide and low‐dose dexamethasone for relapsed/refractory multiple myeloma
- Author
-
Zhaoyang Teng, Andrew Spencer, Catriona Byrne, Wiesław Wiktor Jędrzejczak, Shaji Kumar, Marie-Christine Kyrtsonis, Norbert Grzasko, Meletios A. Dimopoulos, Richard Labotka, Neeraj Gupta, Sebastian Grosicki, and Sosana Delimpasi
- Subjects
Adult ,Boron Compounds ,Male ,medicine.medical_specialty ,Cyclophosphamide ,Nausea ,Glycine ,Administration, Oral ,Phases of clinical research ,Gastroenterology ,Dexamethasone ,Disease-Free Survival ,Ixazomib ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Recurrence ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Clinical endpoint ,Humans ,Medicine ,Aged ,Aged, 80 and over ,business.industry ,Hazard ratio ,Hematology ,Middle Aged ,Survival Rate ,Tolerability ,chemistry ,030220 oncology & carcinogenesis ,Female ,medicine.symptom ,Multiple Myeloma ,business ,030215 immunology ,medicine.drug - Abstract
There is a need for efficacious, convenient treatments with long-term tolerability for patients with relapsed/refractory multiple myeloma (RRMM). This phase 2 study evaluated the all-oral combination of ixazomib, cyclophosphamide and dexamethasone (ICd). Patients with RRMM received ixazomib 4 mg and cyclophosphamide 300 mg/m2 on days 1, 8 and 15, and dexamethasone 40 mg on days 1, 8, 15 and 22 in 28-day cycles. The primary endpoint was overall response rate (ORR). Seventy-eight patients were enrolled (median age 63·5 years). At data cut-off, patients had received a median of 12 treatment cycles; 31% remained on treatment. ORR was 48% [16% very good partial response or better (≥VGPR)]. ORR was 64% and 32% in patients aged ≥65 and
- Published
- 2018